

## **SUMMARY OF PRODUCT CHARACTERISTICS**

### **1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

CYTOPOINT 10 mg Veterinary  
CYTOPOINT 20 mg Veterinary  
CYTOPOINT 30 mg Veterinary  
CYTOPOINT 40 mg Veterinary

### **2. QUALITATIVE AND QUANTITATIVE COMPOSITION**

#### **Active substance:**

Each vial of 1 ml contains:

CYTOPOINT 10 mg Veterinary, solution for injection: Lokivetmab\* 10 mg  
CYTOPOINT 20 mg Veterinary, solution for injection: Lokivetmab\* 20 mg  
CYTOPOINT 30 mg Veterinary, solution for injection: Lokivetmab\* 30 mg  
CYTOPOINT 40 mg Veterinary, solution for injection: Lokivetmab\* 40 mg

\*Lokivetmab is a caninised monoclonal antibody expressed through recombinant techniques in Chinese hamster ovary (CHO) cells

#### **Excipients:**

<b>Qualitative composition of excipients and other constituents</b>
Trehalose dihydrate
Histidine hydrochloride monohydrate
L-Histidine
Polysorbate 80
L-Methionine
Disodium EDTA dihydrate
Water for injections

Clear to opalescent solution without any visible particles.

### **3. CLINICAL INFORMATION**

#### **3.1 Target species**

Dogs.

#### **3.2 Indications for use for each target species**

Treatment of pruritus associated with allergic dermatitis in dogs.  
Treatment of clinical manifestations of atopic dermatitis in dogs.

#### **3.3 Contraindications**

Do not use in cases of hypersensitivity to the active substance or to any of the excipients.  
Do not use in dogs less than 3 kg bodyweight.

#### **3.4 Special warnings**

Lokivetmab may induce transient or persistent anti-drug antibodies. The induction of such antibodies is uncommon and may have no effect (transient anti-drug antibodies) or may result in a noticeable decrease in efficacy (persistent anti-drug antibodies) in animals that responded to treatment previously.

### 3.5 Special precautions for use

#### Special precautions for safe use in the target species:

Avoidance or elimination of the allergen is an important consideration in the successful treatment of allergic dermatitis. When treating pruritus associated with allergic dermatitis with lokivetmab, investigate and treat any underlying causes (e.g. flea allergic dermatitis, contact dermatitis, food hypersensitivity); this product is not intended to be used as a long-term maintenance therapy if the offending allergen(s) can be successfully avoided or eliminated. Furthermore, in cases of allergic dermatitis and atopic dermatitis, it is recommended to investigate and treat complicating factors, such as bacterial, fungal or parasitic infections/infestations (e.g. flea and mange).

It is recommended to monitor dogs for bacterial infections associated with atopic dermatitis, especially during the first weeks of treatment.

If no or limited response is observed within one month after initial dosing, an improvement in response may be observed after administration of a second dose one month later. However, if the animal does not show a better response after the second dose, the veterinary surgeon should consider alternative treatments.

#### Special precautions to be taken by the person administering the veterinary medicinal product to animals:

Hypersensitivity reactions, including anaphylaxis, could potentially occur in the case of accidental self-injection.

Accidental self-injection may result in an immune response to lokivetmab. It is not expected for this to cause any adverse effects, however, repeated self-administration may increase the risk of hypersensitivity reactions.

In case of accidental self-injection, seek medical advice immediately and show the package leaflet or the label to the physician.

#### Special precautions for the protection of the environment:

Not applicable.

### 3.6 Adverse events

Dogs:

Rare (1 to 10 animals / 10,000 animals treated):	Hypersensitivity reaction <sup>1</sup> (anaphylaxis, facial oedema, urticaria) Vomiting <sup>2</sup> , diarrhoea <sup>2</sup> Neurological signs (ataxia, convulsion, seizure)
Very rare (<1 animal / 10,000 animals treated, including isolated reports):	Injection site pain, injection site swelling Clinical signs of immune-mediated diseases (e.g. immune-mediated haemolytic anaemia, immune-mediated thrombocytopenia)

<sup>1</sup> In case of such reactions, appropriate treatment should be administered immediately.

<sup>2</sup> May occur in connection with hypersensitivity reactions. Treatment should be administered as needed.

Reporting suspected adverse reactions after authorization of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Any suspected adverse events should be reported to the Ministry of Health according to the National Regulation by using an online form <https://sideeffects.health.gov.il/>.

### 3.7 Use during pregnancy, lactation or lay

#### Pregnancy and lactation:

The safety of the veterinary medicinal product has not been established during pregnancy and lactation. The use is not recommended during pregnancy and lactation.

Fertility:

Do not use in breeding animals.

**3.8 Interaction with other medicinal products and other forms of interaction**

No drug interactions were observed in field studies where lokivetmab was administered concomitantly with veterinary medicinal products such as endo- and ectoparasiticides, antimicrobials, anti-inflammatories and vaccines.

If a vaccine(s) is to be administered at the same time as treatment with lokivetmab, the vaccine(s) should be administered at a different site to that of lokivetmab.

**3.9 Administration routes and dosage**

Subcutaneous use.

Avoid excessive shaking or foaming of the solution. Administer the entire contents (1 ml) of the vial.

Dose according to the dosing chart below. For dogs above 40 kg, the contents of more than one vial are required to administer a single dose. In those cases, withdraw the appropriate content from each required vial into the same syringe. To allow for mixing of the solution, gently invert the syringe three or four times before administering.

Dosage and treatment schedule:

The recommended minimum dose is 1 mg/kg bodyweight, once a month. The need for repeat or longer-term treatment in dogs with allergic dermatitis should be based on the needs of the individual patient including an assessment by the responsible veterinarian of the ability to avoid/eliminate the allergenic stimulus (see also section 3.5). Dose according to the dosing chart below:

Bodyweight (kg) of dog	CYTOPOINT strength (mg) and number of vials to be administered			
	10 mg	20 mg	30 mg	40 mg
3.0-10.0	1			
10.1-20.0		1		
20.1-30.0			1	
30.1-40.0				1
40.1-50.0	1			1
50.1-60.0			2	
60.1-70.0			1	1
70.1-80.0				2

**3.10 Symptoms of overdose (and where applicable, emergency procedures and antidotes)**

No adverse reactions other than those mentioned in section 3.6 were observed in laboratory overdose studies.

In case of adverse clinical signs after an overdose the dog should be treated symptomatically.

**3.11 Special restrictions for use and special conditions for use, including restrictions on the use of antimicrobial and antiparasitic veterinary medicinal products in order to limit the risk of development of resistance**

Not applicable.

### **3.12 Withdrawal periods**

Not applicable.

## **4 PHARMACOLOGICAL INFORMATION**

### **4.1 ATCvet code: QD11AH91**

### **4.2 Pharmacodynamics**

Lokivetmab is a caninised monoclonal antibody (mAb) specifically targeting canine interleukin-31. The blocking of IL-31 by lokivetmab prevents IL-31 from binding to its co-receptor and thereby inhibits IL-31 mediated cell signalling, providing relief from atopic dermatitis-related pruritus and anti-inflammatory activity.

### **4.3 Pharmacokinetics**

In a laboratory model study lokivetmab demonstrated an onset of efficacy for pruritus by the first time point at 8 hours post administration.

In field studies up to 9 months, treatment of dogs with atopic dermatitis was demonstrated to have a favourable effect on the reduction of pruritus and on the reduction of disease severity as evaluated by Canine Atopic Dermatitis Extent and Severity Index (CADESI) 03 scores. A small number of dogs showed a low, or an absence of, clinical response to lokivetmab. This is likely due to the highly targeted mechanism of action of lokivetmab in the context of a complex disease and heterogeneous pathogenesis. Refer also to section 3.5 of the SPC.

## **5 PHARMACEUTICAL PARTICULARS**

### **5.1 Major incompatibilities**

Do not mix with any other veterinary medicinal product

### **5.2 Shelf life**

Do not use the veterinary medicinal product after the expiry date (exp. date) mentioned on the package. The expiry date refers to the last day of that month.

Shelf life after first opening the immediate packaging: use immediately

### **5.3 Special precautions for storage**

Store in a refrigerator (2 °C – 8 °C). Do not freeze.

Store in the original package.

Protect from light.

### **5.4 Nature and composition of immediate packaging**

Primary packaging: Single dose clear glass Type I vials with chlorobutyl rubber stopper.

Secondary packaging: cardboard box.

Pack sizes:

CYTOPOINT 10 mg solution for injection for dogs:

Cardboard box with 1 vial of 1 ml, 2 vials of 1 ml or 6 vials of 1 ml

CYTOPOINT 20 mg solution for injection for dogs:

Cardboard box with 1 vial of 1 ml, 2 vials of 1 ml or 6 vials of 1 ml

CYTOPOINT 30 mg solution for injection for dogs:

Cardboard box with 1 vial of 1 ml, 2 vials of 1 ml or 6 vials of 1 ml

CYTOPOINT 40 mg solution for injection for dogs:

Cardboard box with 1 vial of 1 ml, 2 vials of 1 ml or 6 vials of 1 ml

Cytopoint LPD

Not all pack sizes may be marketed.

#### **5.5 Special precautions for the disposal of unused veterinary medicinal product or waste materials derived from the use of such products**

Any unused veterinary medicinal product or waste materials from such veterinary medicinal products should be disposed of as a toxic waste. Do not dispose of in the sewage system.

#### **6. MARKETING AUTHORISATION HOLDER**

Zoetis Israel Holding B.V.  
Atir Yeda Street, Kfar Saba, Israel

#### **7. MARKETING AUTHORISATION NUMBER(S)**

CYTOPOINT 10 mg Veterinary: 179-29-37602-00  
CYTOPOINT 20 mg Veterinary: 179-30-37603-00  
CYTOPOINT 30 mg Veterinary: 179-31-37604-00  
CYTOPOINT 40 mg Veterinary: 179-32-37605-00

#### **8. MANUFACTURER**

Zoetis Belgium S.A.  
Rue Laid Burniat 1, 1348 Louvain-la-Neuve Belgium

#### **9. DATE OF REVISION OF THE TEXT**

June 2025